Neovasc was created in 2008 through a merger of two Israeli cardiology start-ups.
Neovasc Inc. (TSXV: NVC) has filed a preliminary base prospectus with the US Securities and Exchange Commission (SEC) and Canadian Securities Administrators to raise up to $200 million on Nasdaq or the Toronto Stock Exchange, and has applied to list on Nasdaq. Neovasc was created in 2008 through a merger of two Israeli cardiology start-ups held by Peregrine Ventures - B-Balloon Ltd. and Neovasc Medical Ltd. - and Canada's Medical Ventures Corporation.
Neovasc's leading products are the Reducer for the treatment of refractory angina and the Tiara technology for trans-catheter treatment of mitral valve disease. The company has a market cap of C$355 million, after a 150% rise in its share price over the past 12 months. The company has an R&D center in Israel. Opko Health Inc. (NYSE: OPK; TASE: OPK), controlled by chairman and CEO Phillip Frost, is an investor.
Published by Globes [online], Israel business news - www.globes-online.com - on April 23, 2014
© Copyright of Globes Publisher Itonut (1983) Ltd. 2014